181 related articles for article (PubMed ID: 28910695)
21. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
[TBL] [Abstract][Full Text] [Related]
22. Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification.
Mahmood R; Altaf C; Ahmed P; Khan SA; Malik HS
Turk J Haematol; 2018 May; 35(2):109-115. PubMed ID: 28588002
[TBL] [Abstract][Full Text] [Related]
23. Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients.
Abel GA; Van Bennekom CM; Stone RM; Anderson TE; Kaufman DW
Leuk Res; 2010 Jul; 34(7):939-41. PubMed ID: 20138359
[TBL] [Abstract][Full Text] [Related]
24. Molecular genetics in myelodysplastic syndromes.
Haferlach T
Leuk Res; 2012 Dec; 36(12):1459-62. PubMed ID: 22986016
[TBL] [Abstract][Full Text] [Related]
25. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
[TBL] [Abstract][Full Text] [Related]
26. Classification and prognostic evaluation of myelodysplastic syndromes.
Cazzola M; Della Porta MG; Travaglino E; Malcovati L
Semin Oncol; 2011 Oct; 38(5):627-34. PubMed ID: 21943669
[TBL] [Abstract][Full Text] [Related]
27. Diagnostics and Prognostication of Myelodysplastic Syndromes.
Zini G
Ann Lab Med; 2017 Nov; 37(6):465-474. PubMed ID: 28840983
[TBL] [Abstract][Full Text] [Related]
28. Morphology, cytogenetics and classification of MDS.
Giagounidis A; Haase D
Best Pract Res Clin Haematol; 2013 Dec; 26(4):337-53. PubMed ID: 24507811
[TBL] [Abstract][Full Text] [Related]
29. The classification of MDS: from FAB to WHO and beyond.
Vardiman J
Leuk Res; 2012 Dec; 36(12):1453-8. PubMed ID: 22940257
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes.
Vallespí T; Imbert M; Mecucci C; Preudhomme C; Fenaux P
Haematologica; 1998 Mar; 83(3):258-75. PubMed ID: 9573680
[TBL] [Abstract][Full Text] [Related]
31. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.
Singh ZN; Huo D; Anastasi J; Smith SM; Karrison T; Le Beau MM; Larson RA; Vardiman JW
Am J Clin Pathol; 2007 Feb; 127(2):197-205. PubMed ID: 17210514
[TBL] [Abstract][Full Text] [Related]
32. Impact of the International Consensus Classification of myelodysplastic syndromes.
Zhang Y; Wu J; Xu Z; Qin T; Qu S; Pan L; Wang H; Sun Q; Li C; Jia Y; Cai W; Yan X; Gong J; Gao Q; Li B; Gale RP; Xiao Z
Br J Haematol; 2023 May; 201(3):443-448. PubMed ID: 36575970
[TBL] [Abstract][Full Text] [Related]
33. [Classification and clinical findings of myelodysplastic syndromes].
Tsuruda K; Hasegawa H; Fuchigami M; Uno N; Morinaga Y; Miyazaki Y; Yanagihara K
Rinsho Byori; 2014 Apr; 62(4):359-68. PubMed ID: 25022065
[TBL] [Abstract][Full Text] [Related]
34. [New advance of research on prognostic factors in myelodysplastic syndrome--review].
Wei J; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1465-72. PubMed ID: 19099666
[TBL] [Abstract][Full Text] [Related]
35. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.
Strupp C; Nachtkamp K; Hildebrandt B; Giagounidis A; Haas R; Gattermann N; Bennett JM; Aul C; Germing U
Leuk Res; 2017 Jun; 57():78-84. PubMed ID: 28324772
[TBL] [Abstract][Full Text] [Related]
36. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
[TBL] [Abstract][Full Text] [Related]
37. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
[TBL] [Abstract][Full Text] [Related]
38. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
[TBL] [Abstract][Full Text] [Related]
39. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
40. The changing classification of myelodysplastic syndromes: what's in a name?
Steensma DP
Hematology Am Soc Hematol Educ Program; 2009; ():645-55. PubMed ID: 20008250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
